Table 1.
Candidate genes and SNPs and genotype frequencies
| Gene symbol | Rs number | Wild type>variant allele | Genotype frequency | Hardy-Weinberg equilibrium (P value) |
| HTR1A | rs6295 | C/G | CC=0.23, GC=0.48, GG=0.29 | 0.73 |
| HTR1B | rs6296 | C/G | CC=0.64, GC=0.29, GG=0.07 | 0.48 |
| HTR2A | rs6313 | G/A | GG=0.42, AG=0.46, AA=0.12 | 0.85 |
| rs6311 | C/T | CC=0.82, TC=0.16, TT=0.01 | 0.58 | |
| TPH1 | rs1800532 | A/C | AA=0.30, CA=0.42, AA=0.27 | 0.18 |
| TPH2 | rs4570625 | G/T | GG=0.53, TG=0.42, TT=0.04 | 0.36 |
| SLC6A4* | rs25531 | A/G | S=0.44, LA=0.52, LG=0.04 | 0.64 |
| CRHR1 | rs110402 | G/A | GG=22, AG=31, AA=16 | 0.43 |
| rs1876831 | C/T | CC=50, TC=17, TT=2 | 0.70 | |
| CNR1 | rs1049353 | G/A | GG=48, AG=18, AA=3 | 0.44 |
| FAAH | rs324420 | A/C | CC=0.63; AC=0.30 AA=0.07 | 0.48 |
| FKBP5 | rs9470080 | A/G | AA=11, GA=34, GG=24 | 0.85 |
| rs3800373 | C/A | CC=9, AC=28, AA=32 | 0.47 | |
| rs1360780 | T/C | TT=9, CT=32, CC=28 | 0.97 | |
| NR3C1 | rs10482672 | G/A | GG=54, AG=14, AA=1 | 0.93 |
| BDNF | rs6265 | G/A | GG=46, AG=20, AA=3 | 0.66 |
| COMT | rs4680 | G/A | GG=19, AG=39, AA=11 | 0.22 |
| SLC1A3 | rs2269272 | C/T | CC=48, TC=20, TT=1 | 0.49 |
*SLC6A4 rs25531 was genotyped as part of the triallelic 5-HTTLPR locus (high activity LA allele; low transcriptional activity S allele, low transcriptional activity LG allele). Alleles were grouped as low activity (SS, S LG, LGLG) (0.23), intermediate activity (S LA, LALG) (0.49) and high activity (LALA) (0.28) variants.
†
BDNF, brain-derived neurotrophic factor; CNR1, cannabinoid receptor type 1; COMT, catechol-O-methyltransferase; CRHR1, corticotropin-releasing hormone receptor 1; FAAH, fatty acid amide hydrolase; FKBP5, FK506 binding protein 5; HTR1A, 5-Hydroxytryptamine Receptor 1A; HTR2A, 5-Hydroxytryptamine Receptor 2A; HTR1B, 5-Hydroxytryptamine Receptor 1B; NR3C1, nuclear receptor subfamily 3 group C member 1; TPH1, tryptophan hydroxylase 1; TPH2, tryptophan hydroxylase 2.